Abstract
Epilepsy remains a significant medical challenge, particularly in drug-resistant cases where surgical intervention may be the only viable treatment option. Identifying the epileptogenic zone, the brain region responsible for seizure initiation, is a critical step in surgical planning. Combining dynamical system models and the neuroimaging data of epileptic patients in a Bayesian framework has previously been shown to be a promising approach to identify the epileptogenic zone. However, previous studies employed coupled neural mass models to describe the whole brain seizure dynamics and hence could only provide a highly coarse spatially estimate of the epileptogenic zone. In this study we propose an extension of the Bayesian virtual epileptic patient framework to a neural field model which could improve the spatial resolution by several orders. Performing model inversion using neural field models is a challenging task since: (i) it is computationally expensive to compute gradients over a neural field simulation and (ii) parameter space can be very high dimensional. We demonstrate that using pseudo-spectral methods and spherical harmonic transforms it is feasible to perform Bayesian model inversion on a neural field extension of the reduced Epileptor model. We found that the neural field extension not only improves the spatial resolution but also significantly reduces the number of false positives.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Fondation pour la Recherche M#x00E9;dicale (Grant DIC20161236442), European Union's Horizon 2020 research and innovation programme under grant agreement No. 945539 (SGA3) Human Brain Project, and the SATT Sud-Est (TVB-Epilepsy). This work has been carried out within the F#x00E9;dration Hospitalo-Universitaire EPINEXT with the support of the Recherche Hospitalo-Universitaire EPINOV (Grant ANR-17-RHUS-0004) funded by the "Investissements d'Avenir" French Government program managed by the French National Research Agency (ANR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed written consent was obtained for all patients in compliance with the ethical requirements of the Declaration of Helsinki, and the study protocol was approved by the ethics committee - Comit#x00E9; de Protection des Personnes sud M#x00E9;diterran#x00E9;e 1
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The patient data sets cannot be made publicly available due to the data protection concerns.
